Items where Author is "Mills, Mackenzie"

Number of items: 16.
Article
  • Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products:evidence from nine OECD countries. (2023) Mills, Mackenzie; Kanavos, Panos picture_as_pdf
  • HTA barriers for conditional approval drugs. (2023) Mills, Mackenzie picture_as_pdf
  • Launch sequencing of pharmaceuticals with multiple therapeutic indications:evidence from seven countries. (2023) Mills, Mackenzie; Michaeli, Daniel; Miracolo, Aurelio; Kanavos, Panos picture_as_pdf
  • Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. (2022) Michaeli, Daniel Tobias; Mills, Mackenzie; Kanavos, Panos picture_as_pdf
  • Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. (2022) Michaeli, Daniel Tobias; Mills, Mackenzie; Michaeli, Thomas; Miracolo, Aurelio; Kanavos, Panos picture_as_pdf
  • Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Mills, Mackenzie; Kanavos, Panos
  • Drivers and methodological considerations associated with the acceptability of real-world evidence for effectiveness/efficacy by regulators and HTAs:evidence from North America, Europe, and Australia. Candore, Gianmario; Martin, Claire; Gabarro, Montse Soriano; Mills, Mackenzie; Kanavos, Panos; Bromley, Susan; Cooper, Amy L.; Wolf, Birgit; Bolot, Paul; Franklin, Joe; Wasem, Jurgen; Schneeweiss, Sebastian; Sculpher, Mark; Civitelli, Diego; Chavez-Montoya, Danitza
  • HTA18 First to launch, first to falter?:an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Civitelli, D.; Politopoulou, K.; Mills, Mackenzie; Kanavos, P.
  • HTA187 Advancing a collaborative value assessment framework for Next-Generation Sequencing/ Comprehensive Genomic Profiling in Europe:building on and enhancing an existing framework - a multi-stakeholder web-Delphi approach. Kanavos, Panos; Alcaraz, OA; Chávez, Danitza; Colaci, C; Haig, Madeleine; Argento, F; Main, Caitlin; Alfie, Verónica; Mills, Mackenzie; Pichon-Riviere, DA; Augustovski, F
  • HTA246 Improving access to innovative therapies for rare bleeding disorders:evidence from high income countries. Alani, A. H.; Eaves, K.; Mills, Mackenzie; Kanavos, P.
  • HTA255 First-in-class drugs in HTA:blunder or bliss? Politopoulou, Konstantina; Mills, Mackenzie; Kanavos, Panos
  • How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. Mills, Mackenzie; Kanavos, Panos picture_as_pdf
  • Sin taxes and their effect on consumption, revenue generation and health improvement:a systematic literature review in Latin America. Miracolo, Aurelio; Sophiea, Marisa; Mills, Mackenzie; Kanavos, Panos picture_as_pdf
  • A systematic review of value criteria for next-generation sequencing/ comprehensive genomic profiling to inform value framework development. Augustovski, Federico; Colaci, Carla; Mills, Mackenzie; Chávez, Danitza; Argento, Fernando; Alfie, Verónica; Pichon Riviere, Andrés; Kanavos, Panos; Alcaraz, Andrea picture_as_pdf
    • Report
  • Controlling expenditure within the Spanish pharmaceutical market: macro- and micro-level policy approaches. Kanavos, Panos; Mills, Mackenzie; Cheatley, Jane; Lopez-Casasnovas, Guillem; Manganelli, Anton; Maynou, Laia; Serra, Miquel
  • Pharmaceutical policy in China. Kanavos, Panos; Mills, Mackenzie; Zhang, Anwen picture_as_pdf